On May, 14 Aimmune Therapeutics, Inc. (AIMT) EPS Estimated At $-0.67

April 17, 2018 - By Benjamin Allen

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Corporate Logo

Aimmune Therapeutics, Inc. (NASDAQ:AIMT)’s earnings report is expected On May, 14., as reported by RTT. This year’s EPS analyst estimate is expected to be $-0.67. That is 28.85 % down compareed to $-0.52 EPS for last year. -17.28 % EPS growth is what Wall Street’s sees after $-0.81 reported EPS last quarter. The stock decreased 1.52% or $0.48 during the last trading session, reaching $31.01.Currently Aimmune Therapeutics, Inc. is uptrending after 29.28% change in last April 17, 2017. AIMT has also 358,288 shares volume. The stock outperformed the S&P500 by 17.73%.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe.The firm is worth $1.80 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.Currently it has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: